Influenza vaccination in primary and secondary immunodeficiencies
PhD ceremony: Mr. S. van Assen, 16.15 uur, Aula Academiegebouw, Broerstraat 5, Groningen
Dissertation: Influenza vaccination in primary and secondary immunodeficiencies
Promotor(s): prof. C.G.M. Kallenberg
Faculty: Medical Sciences
Patients with immunodeficiencies are at increased risk of contracting common and/or opportunistic infections, that might be prevented or mitigated by vaccination. We investigated the humoral and cell-mediated immune (CMI) responses following influenza vaccination in patients with humoral primary immunodeficiencies (hPID), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)-patients treated with rituximab. In patients with hPID humoral responses following influenza vaccination were clearly hampered. Previous vaccination and treatment with intravenous immunoglobulin did not result in higher seroprotection rates. Antibody responses were also decreased in SLE-patients. A second influenza vaccination four weeks later only led to an additional increase in the influenza-specific antibody responses in not previously vaccinated SLE-patients. Influenza vaccination within four to eight weeks after administration of rituximab did not result in a humoral response in rituximab-induced B-cell depleted RA-patients. Six to 10 months following rituximab therapy an antibody response was found although it was still hampered. CMI responses following influenza vaccination were impaired in the hPID, SLE and rituximab-treated RA-patients. In SLE-patients reduced CMI responses were associated with the use of prednisone and/or azathioprine. In conclusion, the patients with primary and secondary immunodeficiencies we investigated demonstrated hampered humoral and CMI responses following influenza vaccination. We developed evidence- and expert-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases for the European League Against Rheumatism (EULAR).
Last modified: | 13 March 2020 01.09 a.m. |
More news
-
06 May 2024
Impact: 'URinControl', treatment of urine loss through app
One of the three researchers nominated for the Ben Feringa Impact Award 2024 is general practicioner and researcher-epidemiologist Anne Loohuis. Loohuis conducted research on the treatment of urine loss through the self-help app URinControl'.
-
29 April 2024
Tactile sensors
Every two weeks, UG Makers puts the spotlight on a researcher who has created something tangible, ranging from homemade measuring equipment for academic research to small or larger products that can change our daily lives. That is how UG...
-
29 April 2024
Royal Decoration awarded to Gerard van den Berg
The Faculty of Economics and Business is very proud to announce that Professor Gerard van den Berg has been appointed Officer of the Order of Orange-Nassau. The decoration was presented to him by Mayor Koen Schuiling of the Municipality of...